Terapia bewacizumabem w raku jajnika – przegląd badań klinicznych

• Authors: Jolanta Lubin , Anna Markowska , Janina Markowska

Title variants

EN

Treatment with bevacizumab in ovarian cancer – clinical trials review

• Languages of publication: EN

Abstracts

EN

Angiogenesis is a process which has been in the focus in the last decade due to its role in the development of can­cers. The identification of vascular endothelial growth factor (VEGF) in the beginning of the 80’s became the new objective of therapies of cancers. The finding of angiogenesis inhibitors has brought the therapy of cancers includ­ing ovarian cancer in a new era. Apart from the “golden standard” such as the taxans and platinum components, the treatment of ovarian cancer has not introduced any new front-line drugs for many years. The registration of bevacizumab has changed data regarding in particular the progression-free survival (PFS), which was confirmed by GOG-0218 and ICON-7 clinical trials. The aim of the article was to put clinical trials that pointed to the effi­ciency of bevacizumab in order as well as presenting those whose results may allow in the nearest future for a wider use of bevacizumab – not only in the front-line chemotherapy of ovarian cancer, but also in neoadjuvant therapy and the treatment of a recurrent neoplasm, both platinum-sensitive and platinum-resistant. Studies of predictive factors, which allow for a group of patients who benefit most from anti-angiogenic drugs treatment to be singled out, are also important. At present, clinical trials and scientific studies are under way and maybe they will help identify patients whose PFS and the overall survival (OS) time is be prolonged as a result of treatment with bevacizumab.

PL

Angiogeneza to proces, na którym w ciągu ostatnich dekad skupiono szczególną uwagę, ponieważ odgrywa on istotną rolę w rozwoju nowotworów. Identyfikacja czynnika wzrostu śródbłonka naczyniowego VEGF (vascular endothelial growth factor) na początku lat 80. ubiegłego stulecia stała się niewątpliwie nowym celem terapii nowo­tworów, a stworzenie leków hamujących angiogenezę umożliwiło wprowadzenie leczenia nowotworów, w tym raka jajnika, w nową erę. Od wielu lat w terapii tego nowotworu, oprócz „złotego standardu”, jakim jest stosowanie tak­sanów i pochodnych platyny, nie wdrożono nowych leków w pierwszej linii leczenia. Rejestracja bewacizumabu zmieniła dane dotyczące szczególnie czasu wolnego do progresji (progression-free survival, PFS), co potwierdziły badania rejestracyjne tego preparatu (GOG-0218 i ICON-7). Celem pracy było usystematyzowanie badań klinicz­nych, które dowiodły skuteczności bewacizumabu, a także przedstawienie tych, których wyniki w najbliższej przy­szłości mogą pozwolić na szersze zastosowanie leku – nie tylko w terapii pierwszej linii chemioterapii raka jajnika, ale także w terapii neoadiuwantowej oraz w leczeniu wznowy raka jajnika zarówno u pacjentek z nowotworem platynowrażliwym, jak i platynoopornym. Dużej uwagi wymagają też badania nad czynnikami predykcyjnymi, umożliwiającymi wyłonienie grupy pacjentów, którzy mogą uzyskać największą korzyść z leczenia lekami antyangio­gennymi. Obecnie trwają badania naukowe i kliniczne, które być może pozwolą zidentyfikować chorych, u których terapia bewacizumabem wydłuży PFS i czas całkowitego przeżycia (overall survival, OS).

Keywords

EN

angiogenesis; angiogeneza; badania kliniczne; bevacizumab; bewacizumab; clinical trials; ovarian cancer; rak jajnika

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Communications
• Journal: Current Gynecologic Oncology
• Year: 2013
• Volume: 11
• Issue: 4
• Pages: 286–294

Contributors

author

Jolanta Lubin

• Klinika Onkologii, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu. Kierownik: prof. dr hab. n. med. Janina Markowska

author

Anna Markowska

• Klinika Perinatologii i Chorób Kobiecych, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu. Kierownik: prof. dr hab. n. med. Krzysztof Drews

author

Janina Markowska

• Klinika Onkologii, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu. Kierownik: prof. dr hab. n. med. Janina Markowska

References

• 1.Folkman J.: What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst. 1990; 82: 4–6.
• 2.Tonini T., Rossi F., Claudio P.P.: Molecular basis of angiogene­sis and cancer. Oncogene 2003; 22: 6549–6556.
• 3.Scappaticci F.A.: Mechanism and future directions for angiogenesis-based cancer therapies. J. Clin. Oncol. 2002; 20: 3902–3927.
• 4.Griffioen A.W., Molema G.: Angiogenesis: potentials for phar­macologic in the treatment of cancer, cardiovascular diseases and chronic inflammation. Pharmacol. Rev. 2000; 52: 237–268.
• 5.Senger D.R., Connolly D.T., Van der Water L. i wsp.: Putrifica­tion and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 1990; 50; 1774–1778.
• 6. Mattei M.G., Borg J.P., Rosnet O. i wsp.: Assignment of vascular endothelial growth factor (VEGF) and placenta growth factor (PLGF) genes to human chromosome 6p12- p21 and 14q24-q31 regions respectively. Genomics 1996; 32: 168–169.
• 7. Schmitt J., Matei D.: Targeting angiogenesis in ovarian cancer. Cancer Treat. Rev. 2012; 38: 272–283.
• 8.Adres; www.ema.europa.eu/docs/en_GB/document_library/ Summary_of_opinion/human/000582/WC500112811.pdf.
• 9.Monk B.J., Choi D.C., Pugmire G., Burger R.A.: Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithe­lial ovarian cancer. Gynecol. Oncol. 2005; 96: 902–905.
• 10.Burger R.A., Brady M.F., Bookman M.A. i wsp.: Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 2011; 365: 2473–2483.
• 11.Burger R.A., Brady M.F., Bookman A.A. i wsp.: Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncol­ogy Group study. J. Clin. Oncol. 2010; 28: 18, supl. LBA1 ASCO Annual Meeting Proceedings.
• 12.Adres: http://oncofacts.com/archives/gynecologic-cancer-up­date-from-the-2011-annual-oncology-meeting.
• 13.Perren T.J., Swart A.M., Pfisterer J. i wsp.: A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 2011; 365: 2484–2496.
• 14.Perren T.J., Swart A.M., Pfisterer J. i wsp.; ICON7 Investiga­tors: A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 2011; 365: 2484–2496.
• 15.Oza A.M., Perren T.J., Swart A.M. i wsp.: ICON 7: final over­all survival results in the GCIG Phase III randomized trial of bevacizumab in women with newly diagnosed epithelial ovar­ian cancer. Presented at the European Cancer Congress in Amsterdam, Netherlands, September 27 – October 1, 2013. ECC Oral Presentation.
• 16.Adres: www.clinicaltrials.gov: NCT01706120.
• 17.Adres: www.clinicaltrials.gov.
• 18.Gonzalez-Martin A., Gladieff L., Stroyakovskiy D. i wsp.: Front-line bevacizumab (Bev) combined with weekly paclitaxel (wPAC) and carboplatin (C) for ovarian cancer (OC): safety results from the concurrent chemotherapy (CT) phase of the OCTAVIa study. Eur. J. Cancer 2011; 47: S528.
• 19.Gonzalez-Martin A., Gladief L., Tholander B. i wsp.: Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly pacl­itaxel for ovarian cancer. Eur. J. Cancer 2013; 49: 3831–3838.
• 20.Colombo N., Selle F., Korach J. i wsp.: Assessment of safety of surgery in ovarian cancer patients treated with front-line carboplatin, paclitaxel and bevacizumab in the ROSiA routine oncology practice study. Presented at the 18th International Meeting of the European Society of Gynaecological Oncol­ogy in Liverpool, UK; October 19–22, 2013. ESGO Oral presentation.
• 21.Adres: www.clinicaltrials.gov: NCT01462890.
• 22.Adres: www.clinicaltrials.gov: NCT00951496.
• 23.Aghajanian C., Blank S.V., Goff B.A. i wsp.: OCEANS: a ran­domized, double-blind, placebo-controlled phase III trial of che­motherapy with or without bevacizumab in patients with plati­num-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J. Clin. Oncol. 2012; 30: 2039–2045.
• 24.Aghajanian C., Finkler N.J., Rutherford T. i wsp.: OCEANS: a phase III multicenter, randomized, blinded, placebo-controlled trial of carboplatin and gemcitabine plus bevacizumab in patients with platinum-sensitive recurrent ovarian, primary peri­toneal, or fallopian tube cancer. Presented at the American Soci­ety of Clinical Oncology 2011 Annual Meeting in Chicago, IL; June 3-7, 2011. ASCO Oral Presentation #LBA5007.
• 25.Aghajanian C., Nycum L.R., Goff B. i wsp.: Updated overall sur­vival analysis in OCEANS, a randomized phase III trial of gem­citabine (G) + carboplatin (C) and bevacizumab (BV) or place­bo (PL) followed by BV or PL in platinum-sensitive recurrent epithelial ovarian (ROC), primary peritoneal (PPC), or fallopi­an tube cancer (FTC). Ann. Oncol. 2012; 23 supl. 9: ix319.
• 26.Pujade-Laurine E., Hilpert F., Weber B. i wsp.: Bevacizumab combined with chemotherapy for platinum-resistant recur­rent ovarian cancer: the AURELIA open-label randomized phase III trial. J. Clin. Oncol. 2014 (w druku). DOI: 10.1200/ JCO.2013.51.4489.
• 27.Witteveen P., Lortholary A., Fehm T. i wsp.: Final overall sur­vival results from AURELIA, an open-label randomised phase III trial of chemotherapy with or without bevacizumab for platinum-resistant recurrent ovarian cancer. Presented at the European Cancer Congress in Amsterdam, Netherlands; September 27 – October 1, 2013. ECC Oral presentation.
• 28.Poveda A.M., Selle F., Hilpert F. i wsp.: Weekly paclitaxel (PAC), pegylated liposomal doxorubicin (PLD) or topotec­an (TOP) ± bevacizumab (BEV) in platinum (PT)-resistant recurrent ovarian cancer (OC): analysis by chemotherapy (CT) cohort in the GCIG AURELIA randomised phase III trial. Ann. Oncol. 2012; 23 supl. 9: ixe17.
• 29.Adres: www.clinicltrials.gov: NCT00565851.
• 30.Rauh-Hain J.A., Guseh S.H., Esselen K.M. i wsp.: Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer. Int. J. Gyne­col. Cancer 2013; 23: 1219–1225.
• 31.Chéreau E., Lambaudie E., Houvenaeghel G.: Morbidity of surgery after neoadjuwant chemotherapy including bevaci­zumab for advanced ovarian cancer. Int. J. Gynecol. Cancer 2013; 23: 1326–1330.
• 32.Pujade-Lauraine E.: Bevacizumab and oral metronomic cyc­lophosphamide in platinum-resistant ovarian cancer. J. Gyne­col. Oncol. 2013; 24: 209–211.
• 33.Zhao H., Du N., Fu Y. i wsp.: Clinical study of intraperitone­al injection bevacizumab (BV) combined with intraperitoneal hyperthermic perfusion chemotherapy (CT) in treatment of malignant ascites of ovarian cancer (OC). J. Clin. Oncol. 2013; 31 supl. ASCO Annual Meeting Abstracts: abstr. 46F.

• Document Type: article